Hudson Valley Investment Advisors Inc. ADV Buys 200 Shares of Balchem Co. (NASDAQ:BCPC)

Hudson Valley Investment Advisors Inc. ADV lifted its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 6.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 3,183 shares of the basic materials company’s stock after purchasing an additional 200 shares during the period. Hudson Valley Investment Advisors Inc. ADV’s holdings in Balchem were worth $453,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BCPC. Signaturefd LLC raised its position in shares of Balchem by 123.0% during the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after purchasing an additional 91 shares during the period. Principal Securities Inc. acquired a new stake in Balchem during the 4th quarter worth approximately $28,000. Bessemer Group Inc. raised its holdings in Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after acquiring an additional 256 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Balchem during the 4th quarter worth $56,000. Finally, YHB Investment Advisors Inc. bought a new stake in Balchem during the 1st quarter worth $69,000. Institutional investors own 87.91% of the company’s stock.

Balchem Stock Down 4.2 %

Shares of BCPC traded down $7.20 during mid-day trading on Monday, reaching $164.27. The company had a trading volume of 255,308 shares, compared to its average volume of 109,700. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of 46.40, a price-to-earnings-growth ratio of 5.63 and a beta of 0.68. Balchem Co. has a 52 week low of $110.74 and a 52 week high of $186.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The firm has a 50-day moving average price of $161.09 and a 200 day moving average price of $153.77.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Friday, May 3rd. The basic materials company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Balchem had a return on equity of 10.94% and a net margin of 12.52%. The business had revenue of $239.66 million during the quarter, compared to analysts’ expectations of $234.12 million. On average, sell-side analysts forecast that Balchem Co. will post 3.91 EPS for the current year.

Insider Activity at Balchem

In related news, Director David B. Fischer sold 5,000 shares of Balchem stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $152.98, for a total transaction of $764,900.00. Following the transaction, the director now directly owns 9,009 shares of the company’s stock, valued at $1,378,196.82. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the transaction, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David B. Fischer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $152.98, for a total transaction of $764,900.00. Following the sale, the director now directly owns 9,009 shares of the company’s stock, valued at approximately $1,378,196.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,679 shares of company stock valued at $2,458,222. Insiders own 1.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. StockNews.com downgraded Balchem from a “buy” rating to a “hold” rating in a research note on Monday, July 29th. HC Wainwright increased their price objective on Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.